STAT3 Therapeutics is an early stage oncology-focused company, dedicated to developing and commercializing drugs that target the activated STAT3 molecule. Our unique approach arrests the activity of the STAT3 dimer using a cyclic decoy that binds to the molecule in a way that is both specific and impactful, without significant toxic side effects.
Learn More
STAT3 activation increases cancer cell proliferation, promotes immunosuppression, and appears in over 70% of all human cancers.
STAT3 plays an important regulatory role in a variety of cancers and is a key factor in non-cancer diseases, such as autoimmune diseases.
With this in mind, STAT3 Therapeutics’ approach to drug development has a broad applicability, with an initial focus on head and neck cancers.
Learn More| Product | Indication | Stage | ||||||
|---|---|---|---|---|---|---|---|---|
S3T-001 |
Head & Neck Squamous Cell |
Pre-Clinical
|
||||||
S3T-002 |
Non-Small Cell Lung Cancer |
Discovery
|
||||||
S3T-003 |
Glioblastoma |
Discovery
|
||||||
S3T-004 |
Melanoma |
Discovery
|
||||||